These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10427157

  • 1. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
    Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F.
    Eur J Endocrinol; 1999 Aug; 141(2):140-4. PubMed ID: 10427157
    [Abstract] [Full Text] [Related]

  • 2. When to stop GnRH analog therapy: the experience of the Italian Study Group for Physiopathology of Puberty.
    Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F.
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():759-64. PubMed ID: 10969918
    [Abstract] [Full Text] [Related]

  • 3. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group.
    Partsch CJ, Heger S, Sippell WG.
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():747-58. PubMed ID: 10969917
    [Abstract] [Full Text] [Related]

  • 4. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [Abstract] [Full Text] [Related]

  • 5. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height.
    Kempers MJ, Otten BJ.
    Eur J Endocrinol; 2002 Nov; 147(5):609-16. PubMed ID: 12444892
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
    Heger S, Partsch CJ, Sippell WG.
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM.
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [Abstract] [Full Text] [Related]

  • 8. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R, Soros A, Jakubowicz S.
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [Abstract] [Full Text] [Related]

  • 9. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
    Bajpai A, Sharma J, Kabra M, Gupta AK, Menon PS.
    Indian Pediatr; 2002 Jul; 39(7):633-9. PubMed ID: 12147888
    [Abstract] [Full Text] [Related]

  • 10. The Influence of GnRH Analog Therapy on Growth in Central Precocious Puberty.
    Głąb E, Wikiera B, Bieniasz J, Barg E.
    Adv Clin Exp Med; 2016 Jul; 25(1):27-32. PubMed ID: 26935495
    [Abstract] [Full Text] [Related]

  • 11. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
    Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM.
    J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
    [Abstract] [Full Text] [Related]

  • 12. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F.
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [Abstract] [Full Text] [Related]

  • 13. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F, Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Borrelli P, Osio D, Mengarda F, De Luca F, Tatò L.
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
    [Abstract] [Full Text] [Related]

  • 14. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.
    Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z.
    Horm Res; 1997 Jul; 47(2):54-61. PubMed ID: 9030968
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment].
    Messaaoui A, Massa G, Tenoutasse S, Heinrichs C.
    Rev Med Brux; 2005 Feb; 26(1):27-32. PubMed ID: 15816337
    [Abstract] [Full Text] [Related]

  • 16. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 17. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
    Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G.
    Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).
    Borges Mde F, Franciscon Pde M, Cambraia TC, Oliveira DM, Ferreira BP, Resende EA, Palhares HM.
    Arch Endocrinol Metab; 2015 Dec; 59(6):515-22. PubMed ID: 26421668
    [Abstract] [Full Text] [Related]

  • 19. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty.
    Liang Y, Wei H, Li J, Hou L, Zhang J, Wu W, Ying Y, Luo X.
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):839-46. PubMed ID: 25719299
    [Abstract] [Full Text] [Related]

  • 20. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty.
    Paterson WF, McNeill E, Young D, Donaldson MD.
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):626-34. PubMed ID: 15521967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.